诺及锐30及诺及灵30R治疗2型糖尿病临床疗效比较.docVIP

诺及锐30及诺及灵30R治疗2型糖尿病临床疗效比较[摘要] 目的 比较诺和锐30与诺和灵30R治疗2型糖尿病（T2DM）的疗效及不良反应。方法 60例T2DM患者随机分为诺和锐30组和诺和灵30R组，分别给予诺和锐30或诺和灵30R 2次/d治疗，治疗3个月后，观察血糖控制情况及低血糖发生情况。结果 ①治疗后两组患者空腹血糖（FPG）、餐后2h血糖（2hPBG）、糖化血红蛋白（HbA1c）均较治疗前明显下降（P＜0.01），但诺和锐30组2hFPG、HbA1c下降更明显（P＜0.05）。②在控制血糖更佳的同时，诺和锐30所需剂量较诺和灵30R减少（P＜0.05）。③诺和锐30组低血糖发生率显著低于诺和灵30R组（P＜0.05）。结论 诺和锐30能更好地降低T2DM血糖水平，减少低血糖反应，减少胰岛素剂量。 [关键词] 诺和锐30；诺和灵30R；2型糖尿病 [中图分类号] R587.1 [文献标识码] B[文章编号] 1673-9701（2011）21-88-02 Comparative Study on Efficacy of Novomix 30 and Novolin 30R for Treatment of Type 2 Diabetes Mellitus ZENG Zhiling Integrated Traditional and Western Medicine Hospital of Guilin City, Guilin 541004, China [Abstract] Objective To compare the efficacy and adverse reaction of Novomix 30 and Novolin 30R in patients with type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes mellitus were divided into two groups at random, they were given Novomix 30 and Novolin 30R twice daily for 3 months, and blood glucose and hypoglycemia were observed. Results①FPG、2hPBG、HbA1c decreased significantly in the two groups after treatment than that before（P＜0.01）. In Novomix 30 group 2hPBG、HbA1c control was superior to Novolin 30R.②Novomix30 group in controlling blood sugar was better at the same time, was needed to all doses reduction than Novolin 30R（P＜0.05）. ③The incidence of hypoglycemia was lower in Novomix 30 group（P＜0.05）. Conclusion For patients with type 2 diabetes mellitus, Novomix 30 can better reduce blood glucose levels and the incidence of hypoglycemia, and can reduce the dosage of insulin. [Key words] Novomix 30; Novolin 30R; Type 2 diabetes mellitus 在我国，糖尿病发病率增长迅速，其中尤以2型糖尿病（T2DM）患者为主，占90%左右。胰岛β细胞是胰岛素的唯一来源。T2DM是慢性进展性疾病，糖毒性和脂毒性等因素可导致β细胞功能逐渐衰退。早期、适时使用胰岛素控制血糖，尽快使血糖达标，减轻糖毒性作用，可使受损的β细胞功能部分恢复。本人分别用诺和锐30与诺和灵30R控制T2DM患者的血糖，比较两者的疗效及安全性，现报道如下。 1资料与方法 1.1一般资料 选择2008年7月～2010年12月在我院内分泌科住院的T2DM患者为观察对象。入选标准：①诊断上符合1999年世界卫生组织（WHO）制定的T2DM诊断标准；②均为通过饮食、运动及口服降糖药治疗血糖控制不理想的T2DM患者。排除标准：1型糖尿病、继发性糖尿病、严重的心肝肾功能不全、糖尿病急性并发症、甲状